Demand for therapeutics, Leronlimab, will sky rock
Post# of 154909
(Total Views: 486)
Posted On: 01/14/2021 1:16:24 PM
Demand for therapeutics, Leronlimab, will sky rocket. (Is there now)
Mutations have become of critical concern.
Phizer vaccine may produce antibodies that only last 90 days.
Mutations will continue, thus, even if Phizer and Moderna vaccines do work against the 2 most recent mutations, more mutations are coming, and new vaccines will be in research probably forever. The world has changed forever.
Phizer and Moderna vaccines have limited efficacy against becoming infected as Fauci said a month ago. Their trials were looking for reduction ONLY in severe/critical virus cases. Mild/moderate case were not disclosed, but were found by apparently digging into the data.
Phizer: 8 vaccinated patients got severe or critical covid-19. That's what was broadcasting globally. However, 1594 vaccinated folks were reported as "Suspicious Infections", not tested, because mild/moderate was not a target of the trials. So these folks, while in the 95% who won't get severe/critical, can still transmit the disease.
Approval of Leronlimab eminent, urgently needed.
https://blogs.bmj.com/bmj/2021/01/04/peter-do...-raw-data/
Mutations have become of critical concern.
Phizer vaccine may produce antibodies that only last 90 days.
Mutations will continue, thus, even if Phizer and Moderna vaccines do work against the 2 most recent mutations, more mutations are coming, and new vaccines will be in research probably forever. The world has changed forever.
Phizer and Moderna vaccines have limited efficacy against becoming infected as Fauci said a month ago. Their trials were looking for reduction ONLY in severe/critical virus cases. Mild/moderate case were not disclosed, but were found by apparently digging into the data.
Phizer: 8 vaccinated patients got severe or critical covid-19. That's what was broadcasting globally. However, 1594 vaccinated folks were reported as "Suspicious Infections", not tested, because mild/moderate was not a target of the trials. So these folks, while in the 95% who won't get severe/critical, can still transmit the disease.
Approval of Leronlimab eminent, urgently needed.
https://blogs.bmj.com/bmj/2021/01/04/peter-do...-raw-data/
(1)
(0)